A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

~27 mi. (Elche, Spain, +127 more cities)

Hospital General Universitario de Elche

BRAF V600E

Colorectal Carcinoma

cetuximab, +3 more drugs

chemotherapy, +1 more type

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

~27 mi. (Elche, Spain, +260 more cities)

Hospital General Universitario de Elche; Servicio de Oncologia

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

~27 mi. (Elche, Spain, +105 more cities)

Hospital General Universitario de Elche ( Site 1155)

Colorectal Adenocarcinoma

bevacizumab, +1 more drug

targeted therapy

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

~27 mi. (Elche, Spain, +186 more cities)

Hospital General Universitario de Elche; Servicio de Oncologia

ER Positive, +3 more biomarkers

Breast Carcinoma

fulvestrant, +2 more drugs

hormone therapy, +1 more type

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

~27 mi. (Elche, Spain, +34 more cities)

H.G.U. de Elche

Clear Cell Renal Cell Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

~27 mi. (Elche, Spain, +62 more cities)

3139---H.G.U. de Elche

ER Negative, +2 more biomarkers

Breast Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

~27 mi. (Elche, Spain, +23 more cities)

Hospital General Universitario de Elche

HRAS Mutation

Non-Small Cell Lung Carcinoma, +1 more condition

tipifarnib

targeted therapy

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

~27 mi. (Elche, Spain, +12 more cities)

Hospital General Universitario de Elche

ERBB2 Amplification, +3 more biomarkers

Breast Carcinoma

fulvestrant, +2 more drugs

hormone therapy, +1 more type

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

~30 mi. (Alicante, Spain, +170 more cities)

Novartis Investigative Site

ER Negative, +4 more biomarkers

Breast Carcinoma

alpelisib, +1 more drug

chemotherapy, +1 more type

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

~30 mi. (Alicante, Spain, +31 more cities)

Novartis Investigative Site

Myelofibrosis

crizanlizumab, +5 more drugs

immunotherapy, +2 more types

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~61 mi. (El Palmar, Spain, +356 more cities)

Hospital Clínico Universitario Virgen de la Arrixaca

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~61 mi. (El Palmar, Spain, +172 more cities)

Hospital Universitario Virgen de la Arrixaca

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy